Gandelman-Marton and Theitler (2023) must be commended for investigating preconceptual folate supplementation as this recommendation is poorly implemented despite robust evidence of its benefits for the child (Kancherla et al., 2022). However, questions are warranted.First, could Gandelman-Marton and Theitler explain why women of childbearing age with epilepsy deserved a focus? There is neither rational nor evidence yet that supplementation could impact on antiseizure medication malformations (Morrow et al., 2009). Furthermore, there is no data to address the optimal dose and it is unclear whether higher doses offer greater protection.Second, the finding that "only (our emphasis) 22% of the women of childbearing age with epilepsy presenting for their first visit to our epilepsy clinic received FA supplementation" (Gandelman-Marton & Theitler, 2023) is meaningless if Gandelman-Marton and Theitler could not provide data about whose women planned pregnancies in their series. Planning pregnancies is a critical issue for outcomes in this population (Zhang et al., 2020).Last, women must be fully informed of the risks of malformation and neurodevelopment disorders associated with antiseizure medications and adequality advised and supported for effective contraception. Valproic acid should be avoided unless indispensable as it is the most harmful and as its harms are transgenerational (Martin et al., 2022). Levetiracetam and lamotrigine the less teratogenic agents (Diav-Citrin et al., 2017;Scheuerle et al., 2019). Effective contraception is particularly important but a challenge as several antiseizure medications, for example, carbamazepine, oxcarbazepine, felbamate and topiramate, increase the metabolism of ethinylestradiol and progestogens, leading to failure (Crawford, 2002. Could Gandelman-Marton and Theitler provide the data about effective contraception in their series?